Sunday, August 30, 2026

CBOE Over 16% Up In The Last 10 Sessions

CBOE Over 16% Up In The Last 10 Sessions

(VIANEWS) - CBOE (VIX) has been up by 16.76% for the last 10 sessions. At 05:08 EST on Tuesday, 9 April, CBOE (VIX) is $15.40.

Concerning CBOE's yearly highs and lows, it's 0.65% up from its 52-week low and 56.06% down from its 52-week high.

Volatility

CBOE's last week, last month's, and last quarter's current intraday variation average was 1.16%, 0.18%, and 3.68%, respectively.

CBOE's highest amplitude of average volatility was 5.90% (last week), 3.66% (last month), and 3.68% (last quarter), respectively.

News about

  • According to FXStreet on Monday, 8 April, "While the S&P 500 and the Dow Jones registered losses, the Nasdaq Composite saw a rise. "
  • According to Business Insider on Monday, 8 April, "The tech-heavy Nasdaq Composite surged 1.2 percent, the S&P 500 added 1.1 percent and the Dow gained 0.8 percent."
  • According to FXStreet on Monday, 8 April, "The full version of today's analysis - today's Stock Trading Alert - is bigger than what you read above, and it includes the additional analysis of the Apple (AAPL) stock and the current S&P 500 futures contract position. ", "Stock prices were rebounding on Friday, with the S&P 500 index gaining 1.11% and closing above the 5,200 level. "

More news about CBOE (VIX).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI's Trust Gap: Microsoft-Mistral Ecosystem Expansion Meets a Governance Deficit in Agentic Adoption
Microsoft is deepening its AI platform bet through simultaneous moves — expanding its Mistral partnership (Copilot Studio, Foundry, European infrastructure capacity) and deepening enterprise AI governance ties with Manulife — just as independent research (Google Cloud, VentureBeat, Box) shows enterprises racing toward agentic AI adoption (100% planned within two years) while data access and trust in agent decisions lag badly (average 45% data access, only ~half trust agent outputs). The result is a structural mismatch between platform-vendor momentum and enterprise readiness to actually govern and trust the agents being deployed.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
Same entity (Morgan Stanley & Co. LLC), same metric (net_income), same fiscal period (Q1 2026), same observation date (2026-03-31), but vastly different values: $5.567 billion vs. $5.57. These cannot coexist for the same time period. Fact B appears to be a data entry error (possible missing decimal placement: 5.57 should likely be 5,567,000,000 or a per-share figure incorrectly entered as total).
We flag conflicts openly ›
Recently verified
Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,257 source documents archived
Query this data → isubstrate.com